Generic placeholder image

Current Cancer Drug Targets

Author(s): Shima Mehrabadi, Mahla Velayati, Nima Zafari, Seyed Mahdi Hassanian, Majid Ghayour Mobarhan, Gordon Ferns, Majid Khazaei and Amir Avan*

DOI: 10.2174/1568009623666221228094557

DownloadDownload PDF Flyer Cite As
Growth-hormone-releasing Hormone as a Prognostic Biomarker and Therapeutic Target in Gastrointestinal Cancer

Page: [346 - 353] Pages: 8

  • * (Excluding Mailing and Handling)

Abstract

Gastrointestinal cancers are prevalent cancers in the world with a poor prognosis, causing about one-half of all cancer deaths in the world. Unfortunately, there is no effective treatment for GI cancers. GHRH and GHRH receptors (GHRH-R) are expressed in various tumoral tissues and cell lines. The inhibition of GHRH-R is a new area of research because it provides a possible means of treating several types of cancer. Recent publications have reported GHRH and GHRH-R expressions in breast, pancreatic, prostate, colon, gastric, ovarian, and lung cancers, along with promising data about the use of GHRH antagonists in the treatment of different cancers. This review aims to summarize the recent studies on the relationship between GHRH and GI cancers and assess whether this hormone can be our target for therapy or used as a prognostic marker for GI cancers.

Graphical Abstract

[1]
Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin., 2011, 61(2), 69-90.
[http://dx.doi.org/10.3322/caac.20107] [PMID: 21296855]
[2]
Kobayashi, H.; Enomoto, A.; Woods, S.L.; Burt, A.D.; Takahashi, M.; Worthley, D.L. Cancer-associated fibroblasts in gastrointestinal cancer. Nat. Rev. Gastroenterol. Hepatol., 2019, 16(5), 282-295.
[http://dx.doi.org/10.1038/s41575-019-0115-0] [PMID: 30778141]
[3]
Kiaris, H.; Chatzistamou, I.; Papavassiliou, A.G.; Schally, A.V. Growth hormone-releasing hormone: Not only a neurohormone. Trends Endocrinol. Metab., 2011, 22(8), 311-317.
[http://dx.doi.org/10.1016/j.tem.2011.03.006] [PMID: 21530304]
[4]
Barabutis, N.; Schally, A.V. Growth hormone-releasing hormone: Extrapituitary effects in physiology and pathology. Cell Cycle, 2010, 9(20), 4110-4116.
[http://dx.doi.org/10.4161/cc.9.20.13787] [PMID: 20962577]
[5]
Barabutis, N.; Schally, A.V.; Siejka, A. P53, GHRH, inflammation and cancer. EBioMedicine, 2018, 37, 557-562.
[http://dx.doi.org/10.1016/j.ebiom.2018.10.034] [PMID: 30344124]
[6]
Bellyei, S.; Schally, A.V.; Zarandi, M.; Varga, J.L.; Vidaurre, I.; Pozsgai, E. GHRH antagonists reduce the invasive and metastatic potential of human cancer cell lines in vitro. Cancer Lett., 2010, 293(1), 31-40.
[http://dx.doi.org/10.1016/j.canlet.2009.12.014] [PMID: 20064686]
[7]
Muñoz-Moreno, L.; Carmena, M.J.; Schally, A.V.; Prieto, J.C.; Bajo, A.M. Stimulation of neuroendocrine differentiation in prostate cancer cells by GHRH and its blockade by GHRH antagonists. Invest. New Drugs, 2020, 38(3), 746-754.
[http://dx.doi.org/10.1007/s10637-019-00831-2] [PMID: 31312936]
[8]
Hohla, F.; Buchholz, S.; Schally, A.V.; Seitz, S.; Rick, F.G.; Szalontay, L.; Varga, J.L.; Zarandi, M.; Halmos, G.; Vidaurre, I.; Krishan, A.; Kurtoglu, M.; Chandna, S.; Aigner, E.; Datz, C. GHRH antagonist causes DNA damage leading to p21 mediated cell cycle arrest and apoptosis in human colon cancer cells. Cell Cycle, 2009, 8(19), 3149-3156.
[http://dx.doi.org/10.4161/cc.8.19.9698] [PMID: 19755849]
[9]
Busto, R.; Schally, A.V.; Varga, J.L.; Garcia-Fernandez, M.O.; Groot, K.; Armatis, P.; Szepeshazi, K. The expression of growth hormone-releasing hormone (GHRH) and splice variants of its receptor in human gastroenteropancreatic carcinomas. Proc. Natl. Acad. Sci. USA, 2002, 99(18), 11866-11871.
[http://dx.doi.org/10.1073/pnas.182433099] [PMID: 12186980]
[10]
Doga, M.; Bonadonna, S.; Burattin, A.; Giustina, A. Ectopic secretion of growth hormone-releasing hormone (GHRH) in neuroendocrine tumors: Relevant clinical aspects. Ann. Oncol., 2001, 12(Suppl. 2), S89-S94.
[http://dx.doi.org/10.1093/annonc/12.suppl_2.S89] [PMID: 11762359]
[11]
Siejka, A.; Barabutis, N.; Schally, A.V. GHRH antagonist MZ-5-156 increases the expression of AMPK in A549 lung cancer cells. Cell Cycle, 2011, 10(21), 3714-3718.
[http://dx.doi.org/10.4161/cc.10.21.17904] [PMID: 22041656]
[12]
Mayo, K.E.; Miller, T.; DeAlmeida, V.; Godfrey, P.; Zheng, J.; Cunha, S.R. Regulation of the pituitary somatotroph cell by GHRH and its receptor. Recent Prog. Horm. Res., 2000, 55, 237-266.
[PMID: 11036940]
[13]
Lin-Su, K.; Wajnrajch, M.P. Growth hormone releasing hormone (GHRH) and the GHRH receptor. Rev. Endocr. Metab. Disord., 2002, 3(4), 313-323.
[http://dx.doi.org/10.1023/A:1020949507265] [PMID: 12424433]
[14]
Uddin, M.A.; Akhter, M.S.; Singh, S.S.; Kubra, K.T.; Schally, A.V.; Jois, S.; Barabutis, N. GHRH antagonists support lung endothelial barrier function. Tissue Barriers, 2019, 7(4), 1669989.
[http://dx.doi.org/10.1080/21688370.2019.1669989] [PMID: 31578921]
[15]
Veldhuis, J. Pulsatile hormone secretion: Mechanisms, significance and evaluation. In: Ultradian Rhythms from Molecules to Mind; Springer, 2008; pp. 229-248.
[http://dx.doi.org/10.1007/978-1-4020-8352-5_10]
[16]
Olarescu, N.C.; Gunawardane, K.; Hansen, T.K.; Møller, N.; Jørgensen, J.O.L. Normal physiology of growth hormone in adults; Endotext, 2019. Available form: https://www.ncbi.nlm.nih.gov/books/NBK279056/
[17]
Ludwig, B.; Ziegler, C.G.; Schally, A.V.; Richter, C.; Steffen, A.; Jabs, N.; Funk, R.H.; Brendel, M.D.; Block, N.L.; Ehrhart-Bornstein, M.; Bornstein, S.R. Agonist of growth hormone-releasing hormone as a potential effector for survival and proliferation of pancreatic islets. Proc. Natl. Acad. Sci. USA, 2010, 107(28), 12623-12628.
[http://dx.doi.org/10.1073/pnas.1005098107] [PMID: 20616039]
[18]
Rick, F.G.; Seitz, S.; Schally, A.V.; Szalontay, L.; Krishan, A.; Datz, C.; Stadlmayr, A.; Buchholz, S.; Block, N.L.; Hohla, F. GHRH antagonist when combined with cytotoxic agents induces S-phase arrest and additive growth inhibition of human colon cancer. Cell Cycle, 2012, 11(22), 4203-4210.
[http://dx.doi.org/10.4161/cc.22498] [PMID: 23095641]
[19]
Schally, A.V.; Perez, R.; Block, N.L.; Rick, F.G. Potentiating effects of GHRH analogs on the response to chemotherapy. Cell Cycle, 2015, 14(5), 699-704.
[http://dx.doi.org/10.1080/15384101.2015.1010893] [PMID: 25648497]
[20]
Muñoz-Moreno, L.; Arenas, M.I.; Carmena, M.J.; Schally, A.V.; Sánchez-Chapado, M.; Prieto, J.C.; Bajo, A.M. Anti-proliferative and pro-apoptotic effects of GHRH antagonists in prostate cancer. Oncotarget, 2016, 7(32), 52195-52206.
[http://dx.doi.org/10.18632/oncotarget.10710] [PMID: 27448980]
[21]
Bodart, G.; Goffinet, L.; Morrhaye, G.; Farhat, K.; de Saint-Hubert, M.; Debacq-Chainiaux, F.; Swine, C.; Geenen, V.; Martens, H.J. Somatotrope GHRH/GH/IGF-1 axis at the crossroads between immunosenescence and frailty. Ann. N. Y. Acad. Sci., 2015, 1351(1), 61-67.
[http://dx.doi.org/10.1111/nyas.12857] [PMID: 26284958]
[22]
Kahán, Z.; Arencibia, J.M.; Csernus, V.J.; Groot, K.; Kineman, R.D.; Robinson, W.R.; Schally, A.V. Expression of growth hormone-releasing hormone (GHRH) messenger ribonucleic acid and the presence of biologically active GHRH in human breast, endometrial, and ovarian cancers. J. Clin. Endocrinol. Metab., 1999, 84(2), 582-589.
[http://dx.doi.org/10.1210/jc.84.2.582] [PMID: 10022420]
[23]
Guo, J.; Schally, A.V.; Zarandi, M.; Varga, J.; Leung, P.C.K. Antiproliferative effect of growth hormone-releasing hormone (GHRH) antagonist on ovarian cancer cells through the EGFR-Akt pathway. Reprod. Biol. Endocrinol., 2010, 8(1), 54.
[http://dx.doi.org/10.1186/1477-7827-8-54] [PMID: 20509930]
[24]
Cui, T.; Schally, A.V. Growth hormone-releasing hormone (GHRH) and its agonists inhibit hepatic and tumoral secretion of IGF-1. Oncotarget, 2018, 9(47), 28745-28756.
[http://dx.doi.org/10.18632/oncotarget.25676] [PMID: 29983893]
[25]
Chopin, L.K.; Herington, A.C. A potential autocrine pathway for growth hormone releasing hormone (GHRH) and its receptor in human prostate cancer cell lines. Prostate, 2001, 49(2), 116-121.
[http://dx.doi.org/10.1002/pros.1125] [PMID: 11582590]
[26]
Stępień, T.; Sacewicz, M.; Ławnicka, H.; Krupiński, R.; Komorowski, J.; Siejka, A.; Stępień, H. Stimulatory effect of growth hormone–releasing hormone (GHRH(1-29)NH2) on the proliferation, VEGF and chromogranin A secretion by human neuroendocrine tumor cell line NCI-H727 in vitro. Neuropeptides, 2009, 43(5), 397-400.
[http://dx.doi.org/10.1016/j.npep.2009.08.005] [PMID: 19747727]
[27]
Hohla, F.; Moder, A.; Mayrhauser, U.; Hauser-Kronberger, C.; Schally, A.; Varga, J.; Zarandi, M.; Buchholz, S.; Huber, R.; Aigner, E.; Ritter, M.; Datz, C. Differential expression of GHRH receptor and its splice variant 1 in human normal and malignant mucosa of the oesophagus and colon. Int. J. Oncol., 2008, 33(1), 137-143.
[http://dx.doi.org/10.3892/ijo.33.1.137] [PMID: 18575759]
[28]
Kovács, M.; Schally, A.V.; Hohla, F.; Rick, F.G.; Pozsgai, É.; Szalontay, L.; Varga, J.L.; Zarándi, M. A correlation of endocrine and anticancer effects of some antagonists of GHRH. Peptides, 2010, 31(10), 1839-1846.
[http://dx.doi.org/10.1016/j.peptides.2010.07.006] [PMID: 20633588]
[29]
Csernus, V.J.; Schally, A.V.; Kiaris, H.; Armatis, P. Inhibition of growth, production of insulin-like growth factor-II (IGF-II), and expression of IGF-II mRNA of human cancer cell lines by antagonistic analogs of growth hormone-releasing hormone in vitro. Proc. Natl. Acad. Sci. USA, 1999, 96(6), 3098-3103.
[http://dx.doi.org/10.1073/pnas.96.6.3098] [PMID: 10077643]
[30]
Zhang, H.; Kong, Q.; Wang, J.; Jiang, Y.; Hua, H. Complex roles of cAMP–PKA–CREB signaling in cancer. Exp. Hematol. Oncol., 2020, 9(1), 32.
[http://dx.doi.org/10.1186/s40164-020-00191-1] [PMID: 33292604]
[31]
Hohla, F.; Schally, A.V.; Szepeshazi, K.; Varga, J.L.; Buchholz, S.; Köster, F.; Heinrich, E.; Halmos, G.; Rick, F.G.; Kannadka, C.; Datz, C.; Kanashiro, C.A. Synergistic inhibition of growth of lung carcinomas by antagonists of growth hormone-releasing hormone in combination with docetaxel. Proc. Natl. Acad. Sci. USA, 2006, 103(39), 14513-14518.
[http://dx.doi.org/10.1073/pnas.0605309103] [PMID: 16983095]
[32]
Rick, F.G.; Schally, A.V.; Szalontay, L.; Block, N.L.; Szepeshazi, K.; Nadji, M.; Zarandi, M.; Hohla, F.; Buchholz, S.; Seitz, S. Antagonists of growth hormone-releasing hormone inhibit growth of androgen-independent prostate cancer through inactivation of ERK and Akt kinases. Proc. Natl. Acad. Sci. USA, 2012, 109(5), 1655-1660.
[http://dx.doi.org/10.1073/pnas.1120588109] [PMID: 22307626]
[33]
Martari, M.; Salvatori, R. Diseases associated with growth hormone-releasing hormone receptor (GHRHR) mutations. Prog. Mol. Biol. Transl. Sci., 2009, 88, 57-84.
[http://dx.doi.org/10.1016/S1877-1173(09)88003-4] [PMID: 20374725]
[34]
Rajabi, M.; Mousa, S. The role of angiogenesis in cancer treatment. Biomedicines, 2017, 5(4), 34.
[http://dx.doi.org/10.3390/biomedicines5020034] [PMID: 28635679]
[35]
Carmeliet, P. VEGF as a key mediator of angiogenesis in cancer. Oncology, 2005, 69(Suppl. 3), 4-10.
[http://dx.doi.org/10.1159/000088478] [PMID: 16301830]
[36]
Ferrara, N. VEGF as a therapeutic target in cancer. Oncology, 2005, 69(Suppl. 3), 11-16.
[http://dx.doi.org/10.1159/000088479] [PMID: 16301831]
[37]
Sacewicz, M.; Ławnicka, H.; Siejka, A.; Stępień, T.; Krupiński, R.; Komorowski, J.; Stępień, H. Inhibition of proliferation, VEGF secretion of human neuroendocrine tumor cell line NCI-H727 by an antagonist of growth hormone-releasing hormone (GH-RH) in vitro. Cancer Lett., 2008, 268(1), 120-128.
[http://dx.doi.org/10.1016/j.canlet.2008.03.041] [PMID: 18486324]
[38]
Muñoz-Moreno, L.; Bajo, A.M.; Prieto, J.C.; Carmena, M.J. Growth hormone-releasing hormone (GHRH) promotes metastatic phenotypes through EGFR/HER2 transactivation in prostate cancer cells. Mol. Cell. Endocrinol., 2017, 446, 59-69.
[http://dx.doi.org/10.1016/j.mce.2017.02.011] [PMID: 28193499]
[39]
Kanashiro, C.; Schally, A.; Zarandi, M.; Hammann, B.; Varga, J. Alterations of EGFR/HER, angiogenesis and apoptosis pathways after therapy with antagonists of growth hormone releasing hormone and bombesin in non-small cell lung cancer. Int. J. Oncol., 2007, 30(4), 1019-1028.
[http://dx.doi.org/10.3892/ijo.30.4.1019] [PMID: 17332943]
[40]
Chen, H.H.W.; Kuo, M.T. Improving radiotherapy in cancer treatment: Promises and challenges. Oncotarget, 2017, 8(37), 62742-62758.
[http://dx.doi.org/10.18632/oncotarget.18409] [PMID: 28977985]
[41]
Fahrenholtz, C.D.; Rick, F.G.; Garcia, M.I.; Zarandi, M.; Cai, R.Z.; Block, N.L.; Schally, A.V.; Burnstein, K.L. Preclinical efficacy of growth hormone-releasing hormone antagonists for androgen-dependent and castration-resistant human prostate cancer. Proc. Natl. Acad. Sci. USA, 2014, 111(3), 1084-1089.
[http://dx.doi.org/10.1073/pnas.1323102111] [PMID: 24395797]
[42]
Villanova, T.; Gesmundo, I.; Audrito, V.; Vitale, N.; Silvagno, F.; Musuraca, C.; Righi, L.; Libener, R.; Riganti, C.; Bironzo, P.; Deaglio, S.; Papotti, M.; Cai, R.; Sha, W.; Ghigo, E.; Schally, A.V.; Granata, R. Antagonists of growth hormone-releasing hormone (GHRH) inhibit the growth of human malignant pleural mesothelioma. Proc. Natl. Acad. Sci. USA, 2019, 116(6), 2226-2231.
[http://dx.doi.org/10.1073/pnas.1818865116] [PMID: 30659154]
[43]
Gesmundo, I.; Dematteis, A.; Fanciulli, A.; Romana, G.F.; Cai, R.; Sha, W. Growth hormone-releasing hormone (GHRH) antagonists increase the sensitivity to radiotherapy in lung cancer cells. In: Endocrine Abstracts; , 2020. Available form: https://www.endocrine-abstracts.org/ea/0070/ea0070yi11
[http://dx.doi.org/10.1530/endoabs.70.YI11]
[44]
Ogilvy-Stuart, A.L.; Stirling, H.F.; Kelnar, C.J.H.; Savage, M.O.; Dunger, D.B.; Buckler, J.M.H.; Shalet, S.M. Treatment of radiation‐induced growth hormone deficiency with growth hormone‐releasing hormone. Clin. Endocrinol. (Oxf.), 1997, 46(5), 571-578.
[http://dx.doi.org/10.1046/j.1365-2265.1997.1790998.x] [PMID: 9231053]
[45]
Paris, F.; Fuks, Z.; Kang, A.; Capodieci, P.; Juan, G.; Ehleiter, D. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science, 2001, 293, 293-297.
[http://dx.doi.org/10.1126/science.1060191]
[46]
Seitz, S.; Rick, F.G.; Schally, A.V.; Treszl, A.; Hohla, F.; Szalontay, L.; Zarandi, M.; Ortmann, O.; Engel, J.B.; Buchholz, S. Combination of GHRH antagonists and docetaxel shows experimental effectiveness for the treatment of triple-negative breast cancers. Oncol. Rep., 2013, 30(1), 413-418.
[http://dx.doi.org/10.3892/or.2013.2435] [PMID: 23624870]
[47]
Muñoz-Moreno, L.; Arenas, M.I.; Schally, A.V.; Fernández-Martínez, A.B.; Zarka, E.; González-Santander, M.; Carmena, M.J.; Vacas, E.; Prieto, J.C.; Bajo, A.M. Inhibitory effects of antagonists of growth hormone-releasing hormone on growth and invasiveness of PC3 human prostate cancer. Int. J. Cancer, 2013, 132(4), 755-765.
[http://dx.doi.org/10.1002/ijc.27716] [PMID: 22777643]
[48]
Engel, J.; Schally, A.; Varga, J.; Halmos, G.; Buchholz, S. GHRH-antagonist in combination with docetaxel chemotherapy induces regression of MX-1 human experimental breast cancers. Cancer Res., 2007, 67(9)(Suppl.), 3568.
[49]
Seitz, S.; Schally, A.V.; Papadia, A.; Rick, F.G.; Szlatonay, L.; Ortmann, O.; Engel, J.; Köster, F.; Buchholz, S. 0141 Combination of antagonists of growth hormone-releasing hormone with docetaxel as potential therapy in breast cancer in a preclinical study. Breast, 2009, 18, S54.
[http://dx.doi.org/10.1016/S0960-9776(09)70172-9]
[50]
Buchholz, S.; Schally, A.V.; Engel, J.B.; Hohla, F.; Heinrich, E.; Koester, F.; Varga, J.L.; Halmos, G. Potentiation of mammary cancer inhibition by combination of antagonists of growth hormone-releasing hormone with docetaxel. Proc. Natl. Acad. Sci. USA, 2007, 104(6), 1943-1946.
[http://dx.doi.org/10.1073/pnas.0610860104] [PMID: 17261802]
[51]
Jaszberenyi, M.; Rick, F.G.; Popovics, P.; Block, N.L.; Zarandi, M.; Cai, R.Z.; Vidaurre, I.; Szalontay, L.; Jayakumar, A.R.; Schally, A.V. Potentiation of cytotoxic chemotherapy by growth hormone-releasing hormone agonists. Proc. Natl. Acad. Sci. USA, 2014, 111(2), 781-786.
[http://dx.doi.org/10.1073/pnas.1322622111] [PMID: 24379381]
[52]
Huang, W.C.; Hung, M.C. Induction of Akt activity by chemotherapy confers acquired resistance. J. Formos. Med. Assoc., 2009, 108(3), 180-194.
[http://dx.doi.org/10.1016/S0929-6646(09)60051-6] [PMID: 19293033]
[53]
Leone, S.; Chiavaroli, A.; Recinella, L.; Di Valerio, V.; Veschi, S.; Gasparo, I.; Bitto, A.; Ferrante, C.; Orlando, G.; Salvatori, R.; Brunetti, L. Growth hormone-releasing hormone (GHRH) deficiency promotes inflammation-associated carcinogenesis. Pharmacol. Res., 2020, 152, 104614.
[http://dx.doi.org/10.1016/j.phrs.2019.104614] [PMID: 31874252]
[54]
Theophanous, E.; Petraki, C.; Scorilas, A.; Komborozos, V.; Veloudis, G.; Varga, J.L.; Zarandi, M.; Schally, A.V.; Koutsilieris, M. The immunohistochemical expression of growth hormone-releasing hormone receptor splice variant 1 is a favorable prognostic marker in colorectal cancer. Mol. Med., 2009, 15(7-8), 242-247.
[http://dx.doi.org/10.2119/molmed.2008.00132] [PMID: 19593408]
[55]
Gan, J.; Ke, X.; Jiang, J.; Dong, H.; Yao, Z.; Lin, Y.; Lin, W.; Wu, X.; Yan, S.; Zhuang, Y.; Chu, W.K.; Cai, R.; Zhang, X.; Cheung, H.S.; Block, N.L.; Pang, C.P.; Schally, A.V.; Zhang, H. Growth hormone-releasing hormone receptor antagonists inhibit human gastric cancer through downregulation of PAK1–STAT3/NF-κB signaling. Proc. Natl. Acad. Sci. USA, 2016, 113(51), 14745-14750.
[http://dx.doi.org/10.1073/pnas.1618582114] [PMID: 27930339]
[56]
Mezey, G.; Treszl, A.; Schally, A.V.; Block, N.L.; Vízkeleti, L.; Juhász, A.; Klekner, Á.; Nagy, J.; Balázs, M.; Halmos, G.; Bognár, L. Prognosis in human glioblastoma based on expression of ligand growth hormone-releasing hormone, pituitary-type growth hormone-releasing hormone receptor, its splicing variant receptors, EGF receptor and PTEN genes. J. Cancer Res. Clin. Oncol., 2014, 140(10), 1641-1649.
[http://dx.doi.org/10.1007/s00432-014-1716-1] [PMID: 24878932]
[57]
Cai, R.; Zhang, X.; Wang, H.; Cui, T.; Halmos, G.; Sha, W.; He, J.; Popovics, P.; Vidaurre, I.; Zhang, C.; Mirsaeidi, M.; Schally, A.V. Synthesis of potent antagonists of receptors for growth hormone-releasing hormone with antitumor and anti-inflammatory activity. Peptides, 2022, 150, 170716.
[http://dx.doi.org/10.1016/j.peptides.2021.170716] [PMID: 34952135]
[58]
Klukovits, A.; Schally, A.V.; Szalontay, L.; Vidaurre, I.; Papadia, A.; Zarandi, M.; Varga, J.L.; Block, N.L.; Halmos, G. Novel antagonists of growth hormone-releasing hormone inhibit growth and vascularization of human experimental ovarian cancers. Cancer, 2012, 118(3), 670-680.
[http://dx.doi.org/10.1002/cncr.26291] [PMID: 21751186]
[59]
Szepeshazi, K.; Schally, A.V.; Groot, K.; Armatis, P.; Halmos, G.; Herbert, F.; Szende, B.; Varga, J.L.; Zarandi, M. Antagonists of growth hormone-releasing hormone (GH-RH) inhibit IGF-II production and growth of HT-29 human colon cancers. Br. J. Cancer, 2000, 82(10), 1724-1731.
[PMID: 10817510]
[60]
Recinella, L.; Chiavaroli, A.; Veschi, S.; Di Valerio, V.; Lattanzio, R.; Orlando, G.; Ferrante, C.; Gesmundo, I.; Granata, R.; Cai, R.; Sha, W.; Schally, A.V.; Brunetti, L.; Leone, S. Antagonist of growth hormone-releasing hormone MIA-690 attenuates the progression and inhibits growth of colorectal cancer in mice. Biomed. Pharmacother., 2022, 146, 112554.
[http://dx.doi.org/10.1016/j.biopha.2021.112554] [PMID: 34923341]
[61]
Barabutis, N.; Siejka, A. The highly interrelated GHRH, p53, and Hsp90 universe. Cell Biol. Int., 2020, 44(8), 1558-1563.
[http://dx.doi.org/10.1002/cbin.11356] [PMID: 32281696]
[62]
Rick, F.G.; Buchholz, S.; Schally, A.V.; Szalontay, L.; Krishan, A.; Datz, C.; Stadlmayr, A.; Aigner, E.; Perez, R.; Seitz, S.; Block, N.L.; Hohla, F. Combination of gastrin-releasing peptide antagonist with cytotoxic agents produces synergistic inhibition of growth of human experimental colon cancers. Cell Cycle, 2012, 11(13), 2518-2525.
[http://dx.doi.org/10.4161/cc.20900] [PMID: 22751419]
[63]
Gesmundo, I.; Granato, G.; Fuentes-Fayos, A.C.; Alvarez, C.V.; Dieguez, C.; Zatelli, M.C.; Congiusta, N.; Banfi, D.; Prencipe, N.; Leone, S.; Brunetti, L.; Castaño, J.P.; Luque, R.M.; Cai, R.; Sha, W.; Ghigo, E.; Schally, A.V.; Granata, R. Antagonists of growth hormone-releasing hormone inhibit the growth of pituitary adenoma cells by hampering oncogenic pathways and promoting apoptotic signaling. Cancers (Basel), 2021, 13(16), 3950.
[http://dx.doi.org/10.3390/cancers13163950] [PMID: 34439107]
[64]
Lamharzi, N.; Schally, A.V.; Koppán, M.; Groot, K. Growth hormone-releasing hormone antagonist MZ-5-156 inhibits growth of DU-145 human androgen-independent prostate carcinoma in nude mice and suppresses the levels and mRNA expression of insulin-like growth factor II in tumors. Proc. Natl. Acad. Sci. USA, 1998, 95(15), 8864-8868.
[http://dx.doi.org/10.1073/pnas.95.15.8864] [PMID: 9671770]